MedTrace Logo

Phase 1 Study of ELX-02 in Healthy Adult Subjects

NCT03309605 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2021-03-16

Study results available
· View outcomes & findings →

Summary

Phase 1 Multiple Ascending Dose Study in Normal Healthy Volunteers

Conditions

Interventions

DRUG

ELX-02

ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • SGS Life Sciences, a division of SGS Belgium NV

    collaborator OTHER

  • Eloxx Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-11
Primary Completion
2019-06-17
Completion
2019-07-17

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03309605 on ClinicalTrials.gov